Pre-clinical evaluation of technetium-99m platelet receptor-binding peptide

Journal of Nuclear Medicine

Volumn 38, Issue 1, 1997, Pages 105-111

  Lister James, John ^a   Vallabhajosula, Shankar ^b   Moyer, Brian R ^b   Pearson, Daniel A ^b   McBride, Bill J ^b   De Rosch, Mark A ^b   Bush, Larry R ^b   Machac, Josef ^b   Dean, Richard T ^b  

^a BAYER PHARMA AG   (Germany)

^b NONE

Author keywords

GPIIb IIIa receptor; peptide; platelet imaging; technetium 99m; thrombosis imaging

Indexed keywords

FIBRINOGEN RECEPTOR; TECHNETIUM 99M; TECHNETIUM 99M FIBRINOGEN RECEPTOR P748; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DRUG DISTRIBUTION; FEMORAL VEIN; LUNG EMBOLISM; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; SCINTISCANNING; THROMBOCYTE AGGREGATION; THROMBOCYTE MEMBRANE; THROMBUS;

ANIMALS; BLOOD PLATELETS; DOGS; MUSCLE, SKELETAL; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PROTEINS; PULMONARY EMBOLISM; RATS; RATS, SPRAGUE-DAWLEY; TECHNETIUM; THROMBOSIS;

EID: 0031021928     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Anderson FA, Wheeler HB, Goldberg RT, et al. A population-based perspective of the hospital incidence and case facility rates of deep vein thrombosis and pulmonary embolism. Ann Intern Med 1991;151:933-938.
2. Dalen JE, Alper JS. Natural history of pulmonary embolism. Prog Cardiovasc Dis 1975;17:257-270.
3. Sasahara AA. Current problems with pulmonary embolism: introduction. In: Sasahara AA, Sonnenblick EH, Lesch M. eds. Pulmonary Embolism. New York: Grune and Stratton; 1975:1-4.
4. Sasahara AA, Hyers TM, Cole CM, et al. The urokinase pulmonary embolism trail: a national cooperative study. Circulation 1973;47(suppl 2):67-90.
5. Oudkerk M, van Beek EJR, van Putten WLJ, Buller HR. Cost-effectiveness analysis of various strategies in the diagnostic management of pulmonary embolism. Arch Intern Med 1993;153:947-954.
6. Sasahara AA, Cella G, Palla A, Sharma GVRK. Acute pulmonary embolism. In: Kwaan HC, Samama MM. eds. Clinical Thrombosis. Boca Raton: CRC Press; 1989:117-133.
7. Cheely R, McCartney WH, Perry JR, et al. The role of noninvasive tests versus pulmonary angiography in the diagnosis of pulmonary embolism. Amer J Med 1981;70:17-22.
8. Porter J, Hershel J. Drug-related deaths among medical inpatients. JAMA 1977;237: 879-881.
9. Wagner HNL, Lopez-Majano V, Langan JK, Joshi RC. Radioactive xenon in the differential diagnosis of pulmonary embolism. Radiology 1968;91:1168-1184.
10. Biello DR, Mattar AG, McKnight RC, Siegel BA. Ventilation perfusion studies in suspected pulmonary embolism. Am J Roentgenol 1979;133:1033-1037.
11. The PIOPED Investigation. Value of the ventilation/perfusion scan in acute pulmonary embolism: results of the Prospective Investigation of Pulmonary Embolism Diagnosis (PIOPED). JAMA 1990;263:2753-2759.
12. Hull RD, Hirsh J, Carter CJ, et al. Pulmonary angiography, ventilation lung scanning and venography for clinically suspected pulmonary embolism with abnormal perfusion lung scan. Ann Intern Med 1983;98:891-899.
13. Kelley MA, Carson JL, Palevsky MI, Schwartz JA. Diagnosing pulmonary embolism: new facts and strategies. Ann Intern Med 1991;114:300-306.
14. Rose SC, Zwiebel WJ, Nelson BD, et al. Symptomatic lower extremity deep venous thrombosis: accuracy, limitations and role of color duplex flow imaging in diagnosis. Radiology 1990;175:639-644.
15. Davidson BL, Elliott CG, Lensing AWA. Low accuracy of color doppler ultrasound in the detection of proximal leg vein thrombosis in asymptomatic high-risk patients. Ann Intern Med 1992;117:735-738.
16. Som P, Oster ZH. Thrombus-specific imaging: approaching the elusive goal. J Nucl Med 1994;35:202-203.
17. Knight LC. Radiopharmaceuticals for thrombus detection. Semin Nucl Med 1990;20: 52-67.
18. Koblik PD, De Nardo GL, Berger HJ. Current status of immunoscintigraphy in the detection of thrombosis and thromboembolism. Semin Nucl Med 1989;19:221-237.
19. Bautovich G, Angelides S, Lee FT, et al. Detection of deep venous thrombi and pulmonary embolus with technetium-99m-DD-3B6/22 anti-fibrin monoclonal antibody fab' fragment. J Nucl Med 1994;35:195-203.
20. Pearson DA, Lister-James J, Mc Bride WJ, et al. Thrombus imaging using technetium-99m-labeled high-potency GPIIb/IIIa receptor antagonists. Chemistry and initial biological studies. J Med Chem 1996;39:1372-1382.
21. Muto, P, Lastoria S, Varrella P, et al. Detecting deep venous thrombosis with technetium-99m-labeled synthetic peptide P280. J Nucl Med 1995;36:1384-1391.
22. Lister-James J, Knight LC, Maurer AH, Bush LR, Moyer BR, Dean RT. Thrombus imaging with a technetium-99m-labeled, activated platelet receptor-binding peptide. J Nucl Med 1996;37:775-781.
23. Cotton FA, Lippard SJ. Chemical and structural studies of the rhenium (V) oxyhalide complexes. I. Complexes from rhenium (III) bromide. Inorg Chem 1966;5:9-16.
24. Zucker MB. Platelet aggregation measured by the photometric method. Methods Enzymol 1989;169:117-133.
25. Knight LC, Maurer AH, Ammar IA, Epps LA, Dean RT, Pak KY. Technetium-99m-antifibrin Fab′ fragments for imaging venous thrombi: evaluation in a canine model. Radiology 1989;173:163-169.
26. Hasting GE, Seery DS, Vine DL. Recent developments in the diagnosis, treatment and prevention of pulmonary embolism. Arch Fam Med 1993;2:655-669.
27. Hawiger J. Adhesive interactions of blood cells and the vessel wall. In: Coleman R, Hirsh J, Marder V, Salzman E, eds. Hemostasis and thrombosis. Basic principles and clinical practice, 2nd ed. Philadelphia: JB Lippincott Co.; 1987:182-209.
28. Samanen J, Ali F, Romoff T, et al. Development of a small RGD peptide fibrinogen receptor antagonist with potent antiaggregatory activity in vitro. J Med Chem 1991;34:3114-3125.
29. Barker PL, Bullens S, Bunting S, et al. Cyclic RGD peptide analogues as antiplatelet antithrombotics. J Med Chem 1992;35:2040-2048.
30. Alig L, Edenhofter A, Hadvary P, et al. Low molecular weight, nonpeptide fibrinogen receptor antagonists. J Med Chem 1992;35:4393-4407.
31. Cook NS, Bruttger O, Pally Ch, Hagenbach A. The effects of two synthetic glycoprotein IIb/IIIa antagonists, Ro 43-8857 and L-700,462, on platelet aggregation and bleeding in guinea-pigs and dogs: evidence that Ro 43-8857 is orally active. Thromb Haemost 1993;70:838-847.
32. Ramjit DR, Lynch JJ, Sitko GR, et al. Antithrombotic effects of MK-0852, a platelet fibrinogen receptor antagonist, in canine models of thrombosis. J Pharmacol Exp Ther 1993;266:1501-1511.
33. Zablocki JA, Miyano M, Garland RB, et al. Potent in vitro and in vivo inhibitors of platelet aggregation based upon the Arg-Gly-Asp-Phe sequence of fibrinogen. A proposal on the nature of the binding interaction between the Arg-guanidine of RGDX mimetics and the platelet GP IIb-IIIa receptor. J Med Chem 1993;36:1811-1819.
34. Scarborough RM, Naughton A, Teng W, et al. Design of potent and specific integrin antagonists. J Biol Chem 1993;268:1066-1073.
35. 3 antagonists. J Med Chem 1994;37:1-9.
36. Mousa SA, Bozarth JM, Forsythe MS, et al. Antiplatelet and antithrombotic efficacy of DMP 728, a novel platelet GPIIb/IIIa receptor antagonist. Circulation 1994;89:3-12.
37. 3 as an antithrombotic target. Perspect Drug Discov Des 1993;1:537-548.